TCI GENE Inc.
TWO: 6879.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yung Hsiang Lin
- Headquarters
- Taipei, Taiwan
- IPO year
- 2022
- Market cap
- NT$952.5M
- Website
- https://www.genext.me
Loading 6879…
Loading profile data…Frequently asked questions about 6879
What does TCI GENE Inc. (6879.TWO) do?
TCI GENE Inc. provides precision preventive medicines in Taiwan. It offers genetic testing for nutrient metabolism and weight management; G2 and ACE2 genetic testing; supplements; skin care, antiaging, kids' growth, and Alzheimer disease products; and serum for DNA types. The company also provides nutrition consultation services. TCI GENE Inc. i...
Where does 6879.TWO trade?
TCI GENE Inc. (6879.TWO) trades on the Taipei Exchange.
What sector is 6879.TWO in?
TCI GENE Inc. (6879.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TCI GENE Inc.?
Yung Hsiang Lin is the chief executive officer of TCI GENE Inc. (6879.TWO).
Where is TCI GENE Inc. headquartered?
TCI GENE Inc. is headquartered in Taiwan.
Does 6879.TWO pay a dividend?
Yes — TCI GENE Inc. (6879.TWO) paid a trailing twelve-month dividend of TWD 2.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 6879.TWO go public?
TCI GENE Inc. (6879.TWO) completed its initial public offering in 2022.